Insurance Coverage Differs by Demographics, Cancer Type
the Cancer Therapy Advisor take:
Patient demographics and cancer type are major contributing factors for the variation in rates of insurance coverage, according to an article published online in the journal Cancer.
Participants of this study included 688,794 patients between the ages of 18 to 64 years with a diagnosis of one of the top 25 incident cancers between 2007 and 2010 in the Surveillance, Epidemiology, and End Results (SEER) database.
The patients were analyzed based on characteristics, such as age, race, sex, marital status, residency, and county-level demographics (e.g., percent poverty level). The individual’s insurance status was determined to be non-Medicaid insurance, Medicaid coverage, or no insurance.
Results showed nonwhite, younger age males, unmarried, residence in counties with higher levels of poverty, and rural residence were associated with being uninsured versus having non-Medicaid insurance (all P<0.001).
Patients with prostate cancer, melanoma, and thyroid cancer had the highest non-Medicaid insurance rates (92.3%, 92.5%, and 89.5%, respectively), while patients with cervical, liver, and stomach cancer had the lowest rates of non-Medicaid insurance (64.2%, 67.9%, 70.9%, respectively;P<0.001).
The majority of uninsured patients reported cases of lung cancer (14.9%), colorectal cancer (12.1%), and breast cancer (10.2%) (all P<0.001).
Lung cancer was found to cause the majority of cancer mortality across all insurance categories.
Patient demographics and cancer type are major contributing factors for the variation in rates of insurance coverage.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer